|
Sign In to gain access to subscriptions and/or personal tools.
|
Approach to the Assessment of Platelet Function: Comparison between Optical-based Platelet-rich Plasma and Impedance-based Whole Blood Platelet Aggregation Methods
Anna M. Dyszkiewicz-Korpanty, MD
Department of Medicine, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Eugene P. Frenkel, MD
Department of Medicine, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Ravindra Sarode, MD
Department of Pathology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Platelet aggregation studies play an important role in the assessment of hereditary and acquired platelet function defects. The first aggregation test introduced into laboratory practice used platelet-rich plasma (PRP) where aggregation was detected by an optical method. The assessment of platelet function using whole blood (WB) aggregation by an impedance method followed up nearly 20 years later. The WB impedance aggregation assay appears to be superior to the optical method because it 1) evaluates platelets in a physiologic milieu in the presence of red and white blood cells, which are known to modulate platelet function; 2) is faster; 3) has higher sensitivity; and 4) does not require centrifugation, thus avoiding injury to platelets and loss of giant thrombocytes. These two assays were compared. Clearly, the WB impedance aggregation methodology has many advantages over the optical PRP assay for the assessment of the hyperactive platelet syndrome and the effects of anti-platelet drugs.
Key Words: Optical platelet aggregation Whole blood impedance aggregation Hyperactive platelet syndrome Antiplatelet drugs
Clinical and Applied Thrombosis/Hemostasis, Vol. 11, No. 1,
25-35 (2005)
DOI: 10.1177/107602960501100103

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. H.R. Rao
Need for a Point-of-Care Assay for Monitoring Antiplatelet and Antithrombotic Therapies
Stroke,
June 1, 2009;
40(6):
2271 - 2272.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ang and E. Mahmud
Monitoring oral antiplatelet therapy: is it justified?
Therapeutic Advances in Cardiovascular Disease,
December 1, 2008;
2(6):
485 - 496.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lordkipanidze, C. Pharand, T. A. Nguyen, E. Schampaert, D. A. Palisaitis, and J. G. Diodati
Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients
Eur. Heart J.,
December 1, 2008;
29(23):
2877 - 2885.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Velik-Salchner, S. Maier, P. Innerhofer, W. Streif, A. Klingler, C. Kolbitsch, and D. Fries
Point-of-Care Whole Blood Impedance Aggregometry Versus Classical Light Transmission Aggregometry for Detecting Aspirin and Clopidogrel: The Results of a Pilot Study
Anesth. Analg.,
December 1, 2008;
107(6):
1798 - 1806.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lordkipanidze, C. Pharand, E. Schampaert, J. Turgeon, D. A. Palisaitis, and J. G. Diodati
A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
Eur. Heart J.,
July 2, 2007;
28(14):
1702 - 1708.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. T. Ivandic, E. Giannitsis, P. Schlick, P. Staritz, H. A. Katus, and T. Hohlfeld
Determination of Aspirin Responsiveness by Use of Whole Blood Platelet Aggregometry
Clin. Chem.,
April 1, 2007;
53(4):
614 - 619.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. T. Ivandic, P. Schlick, P. Staritz, K. Kurz, H. A. Katus, and E. Giannitsis
Determination of Clopidogrel Resistance by Whole Blood Platelet Aggregometry and Inhibitors of the P2Y12 Receptor
Clin. Chem.,
March 1, 2006;
52(3):
383 - 388.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|